<DOC>
	<DOCNO>NCT00883272</DOCNO>
	<brief_summary>The purpose study determine Femeralle ( DT56a ) effect coagulation system , measure platelet adhesion aggregation , normal thrombophilic postmenopausal woman .</brief_summary>
	<brief_title>Effect DT56a ( Femarelle ) Coagulation System Treatment Postmenopausal Women</brief_title>
	<detailed_description>Women use hormone therapy ( HT ) increase relative risk venous thromboembolism ( VTE ) . The frequency inherit Factor V Leiden risk factor VTE general population estimate 5-10 % . This population 5-21 fold great risk develop VTE . Therefore , give high thrombotic risk combination hormone use hereditary prothrombotic abnormality woman 's symptom frequently go untreated lack alternative therapy . DT56a ( Femarelle ) soy derive compound show act novel selective estrogen receptor modulator ( SERM ) alleviation menopausal symptom prevention postmenopausal bone loss without effect endometrium sex hormone blood profile . The research question current study ass effect femeralle coagulation system determine reasonable safe alternative treatment menopausal symptom thrombophilic woman .</detailed_description>
	<mesh_term>Thrombophilia</mesh_term>
	<criteria>No previous exogenous estrogen exposure Symptomatic Menopause : hot flash , sleep disturbance , symptom relate estrogen deficiency Menopausal ( see ) History bleed thrombotic disorder History malignancy ( particularly Breast Cancer ) Diabetics Coronary Artery Disease Liver Disease Concurrent Anticoagulation therapy</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Menopause</keyword>
	<keyword>Thrombophilia</keyword>
	<keyword>factor V Leiden</keyword>
	<keyword>Estrogen Replacement Therapy</keyword>
	<keyword>Hypercoagulability</keyword>
	<keyword>Venous Thrombosis</keyword>
</DOC>